title: Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes.
abstract: BACKGROUND
  Anemia occurs frequently in patients with cancer and is associated with impaired health-related quality of life (HRQOL). Treatment of anemia results in significant improvements in energy, activity and overall HRQOL, particularly among patients with mild-to-moderate anemia. Importantly, studies have indicated that anemia may have a negative impact on the success of radiotherapy, reducing survival and locoregional control. Recent preclinical and preliminary clinical data have also suggested that anemia may be associated with poorer outcomes following chemotherapy or surgery.
  
  
  METHODS
  Data for review were identified and selected from searches of the literature published from January 1990 through to October 2002 using Medline, and searches of proceedings from key international oncology and hematology meetings.
  
  
  RESULTS
  A wealth of data indicate that treatment of anemia improves HRQOL in patients with cancer. Prospective studies exploring survival and/or treatment outcomes in anemic cancer patients are currently in their early stages, preventing any firm conclusions from being drawn, although they do indicate a benefit in treating anemia.
  
  
  CONCLUSIONS
  Recent studies support the use of erythropoietic agents in anemic cancer patients as a means of raising their hemoglobin levels and consequently improving their HRQOL. Randomized, controlled trials are needed to determine whether treating anemia with erythropoietic agents will improve other outcomes following therapy.
authors.affiliation: Institute for Health Services Research and Policy Studies, Northwestern University, Evanston, IL, USA. d-cella@northwestern.edu
authors.forename: D
authors.initials: D
authors.lastname: Cella
authors.forename: D
authors.initials: D
authors.lastname: Dobrez
authors.forename: J
authors.initials: J
authors.lastname: Glaspy
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005221:Fatigue; D006304:Health Status; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013534:Survival; D016896:Treatment Outcome
chemical_list: D004921:Erythropoietin; D000068256:Darbepoetin alfa